Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

ENDURE - Efficacy and Safety of AOP2014 With CML Patients in Remission (ENDURE-CML-IX)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03117816
Recruitment Status : Recruiting
First Posted : April 18, 2017
Last Update Posted : May 21, 2019
Sponsor:
Collaborators:
Deutsche Krebshilfe e.V., Bonn (Germany)
AOP Orphan Pharmaceuticals AG
Information provided by (Responsible Party):
Kerstin Balthasar, Philipps University Marburg Medical Center

Brief Summary:
A randomized, open-label assessor blinded, multi-center, controlled phase II Trial to evaluate the efficacy of AOP2014 administered bi-weekly subcutaneously (s.c.) in preventing molecular relapse (loss of MMR) in CML patients, who discontinue ABL tyrosine kinase inhibitor therapy (TKI) in deep molecular remission of MR4 or better (MR4.5, or MR5).

Condition or disease Intervention/treatment Phase
Chronic Myeloid Leukemia in Remission Drug: AOP2014 / Pegylated-Proline-interferon alpha-2b Other: Surveillance Phase 2

Detailed Description:

Four hypotheses are tested in hierarchical order. To avoid inflation of type 1 error (false rejection of a null hypothesis), further confirmatory testing has to be stopped as soon as a null hypothesis could not be rejected.

All four hypotheses are tested at significance level 0.05. Null hypotheses 1, 2, and 4 deal with probabilities of molecular relapse-free survival 7, 13, and 25 months after randomisation, respectively; arms A and B are compared with the uncorrected chi-square test. Null hypothesis 3 investigates molecular relapse-free survival as a time-to-event variable; the two arms are compared with the log-rank test


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 214 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Masking Description: A randomized, open-label assessor blinded, multi-center, controlled phase II trial
Primary Purpose: Prevention
Official Title: Efficacy and Safety of Pegylated Proline Interferon Alpha 2b (AOP2014) in Maintaining Deep Molecular Remissions in Patients With Chronic Myeloid Leukemia (CML) Who Discontinue ABL-Kinase Inhibitor Therapy - a Randomized Phase II, Multicenter Trial With Post-study Follow-up
Actual Study Start Date : May 4, 2017
Estimated Primary Completion Date : September 2021
Estimated Study Completion Date : December 2024


Arm Intervention/treatment
Experimental: investigational arm A
There will be an overlapping treatment with AOP2014 and TKI for one month. After one month, the TKI therapy will be stopped and patient will receive only AOP2014 treatment for the next 14 months.
Drug: AOP2014 / Pegylated-Proline-interferon alpha-2b
AOP2014 as pre-filled auto-injection pen for subcutaneous injection, containing 250 µg AOP2014 / 0.5 ml. The solution also contains inactive ingredients (sodium chloride, polysorbate 80, benzyl alcohol, sodium acetate, and acetic acid). The solution is colorless to light yellow.

surveillance arm B
This is an open-label study with a "surveillance" group as comparator arm. Similar as in the arm A, patient will discontinue TKI therapy one month after randomization. From then on patient will receive no further CML treatment.
Other: Surveillance
For patients randomized into this treatment arm stopp their standard treatment and will just be under observation.




Primary Outcome Measures :
  1. RFS 7 [ Time Frame: 7 months after randomization ]
    The primary efficacy endpoint is molecular relapse free survival, RFS 7 months after randomization. Relapse is defined as loss of major molecular remission, MMR, which is any increase of the BCR-ABL ratio to > 0.1% according to the international scale (IS). Time to relapse is defined as the time from randomization to relapse


Secondary Outcome Measures :
  1. RFS 13 [ Time Frame: 13 months after randomization ]
    The relapse free survival, RFS 13 months after randomization

  2. RFS 25 [ Time Frame: 25 months after randomization ]
    The relapse free survival, RFS 25 months after randomization

  3. Number of participants with treatment-related adverse events as assessed by CTCAE v4.03 [ Time Frame: Day 0 - Month 15 (Arm B) or Month 16 (additional safety visit one month after last application for Arm A) ]
    Adverse events, serious adverse events (AEs, SAEs)• Safety, tolerability and toxicity based on incidences of adverse events, serious adverse events

  4. Quality of life measured by EORTC QLQ-C30 [ Time Frame: Day 0 - Month 25 ]
    The data will be compared between the treatment groups and to QoL of normal population.

  5. Quality of life measured by EORTC-QLQ-CML24 [ Time Frame: Day 0 - Month 25 ]
    The data will be compared between the treatment groups and to QoL of normal population. Furthermore, results of the CML24 module should be shared with the EORTC group to complete the validation of this questionnaire

  6. detection of blood parameter 95 CD86+pDC as RFS predictor [ Time Frame: Day 0 - Month 15 ]
    To validate the value of 95 CD86+pDC / 105 lymphocytes at baseline (before TKI stop) as a predictor of RFS

  7. OS (overall survival) [ Time Frame: Day 0 - Month 25 (plus annual post study follow up Months 36,48,60) ]
    Overall survival (OS), defined as the time between the date of randomization and the date of death from any cause.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Signed written informed consent form.
  2. Capability and willingness to comply with study procedures and ability to self-administration of the study drug.
  3. Male or female aged ≥ 18 years.
  4. At least three years of TKI therapy.
  5. BCR-ABL-positive, chronic phase CML patients with a transcript level according to the international scale (IS) of at least MR4, or better (MR4.5, MR5). MR4 is defined as (i) detectable disease ≤0.01% BCR-ABL IS or (ii) undetectable disease in cDNA with ≥10,000 ABL or ≥24,000 GUS transcripts for at least one year. There have to be at least three consecutive PCR-results with MR4 or better within the last year (+ months) before study entry. The latest of these PCRs must be a confirmatory MR4 measurement prior to randomization by the EUTOS-certified Study Reference Laboratories for PCR (BCR-ABL mRNA). No PCR-results in the last year before randomisation can be worse than MR4. If the last PCR was not done within two months from baseline (day 0) in an EUTOS-certified study Reference Laboratory; the PCR sample must be sent to an EUTOS-certified study Reference Laboratory at screening.
  6. Patients who had failed to discontinue TKI in a prior discontinuation attempt are eligible for this protocol, if they fulfil criterion 5 after retreatment with TKI. A prior TKI discontinuation failure must be specifically indicated at inclusion and documented.
  7. Adequate organ function:

    especially total bilirubin, lactate dehydrogenase [LDH], aspartate aminotransferase [AST], alanine aminotransferase [ALT] and coagulation parameters ≤ 2 × upper limit of normal (ULN)

  8. Adequate hematological parameters:

    platelet count ≥ 100 × 1000000000/L; white blood cell count ≥ 2.5 × 1000000000/L; lymphocytes ≥ 1.0 × 1000000000/L; hemoglobin ≥ 9.0 g/dL or 5.59 mmol/L.

  9. Female patients with reproductive potential must agree to maintain highly effective methods of contraception by practicing abstinence or by using at least two methods of birth control from the date of consent through the end of the study. If abstinence could not be practiced, a combination of hormonal contraceptive (oral, injectable, or implants) and a barrier method (condom, diaphragm with a vaginal spermicidal agent) has to be used. Male patients must agree to use condoms during study participation.
  10. Negative serum pregnancy test in women of childbearing potential.
  11. Date of diagnosis of CML confirmed by laboratory PCR must be known.

Exclusion Criteria:

  1. Rare variants of BCR-ABL not quantifiable by RT-PCR according to the international scale (IS).
  2. Current or previous autoimmune diseases requiring treatment.
  3. Immunosuppressive treatment of any kind; transplant recipients
  4. Prior allogeneic stem cell transplantation.
  5. Prior pegylated IFN therapy. Prior low dose conventional IFN treatment with ≤ 3 x 3 Mio I.E. / week for less than 1 year is acceptable.
  6. History of TKI resistance within the last 4 years of TKI therapy.
  7. History of accelerated phase or blast crisis.
  8. Hypersensitivity/allergy to the active substance or excipients of the formulation.
  9. Severe hepatic dysfunction or decompensated cirrhosis.
  10. End stage renal disease (GFR <15 ml/min)
  11. Thyroid disease that cannot be controlled by conventional therapy.
  12. Uncontrolled diabetes mellitus
  13. Epilepsy or other disorders of the central nervous system.
  14. Severe cardiac disease history including unstable or uncontrolled cardiac disease in the previous 6 months.
  15. Uncontrolled hypertension
  16. Any history of retinopathy e.g. retinal detachment, degeneration or thromboembolic events.
  17. Clinically significant concomitant diseases or conditions, which, in the opinion of the investigator, would lead to an unacceptable risk for the patient to participate in the study (please refer also to the actual Investigator Brochure).
  18. Other malignancy, except adequately treated superficial bladder cancer, basal or squamous cell carcinoma of the skin, or other cancer(s) for which the patient has been disease free for more than 3 years.
  19. Active or uncontrolled infections at the time of randomization.
  20. Pregnant and/or nursing women.
  21. Use of antibiotic therapy within the last 2 weeks prior to randomization
  22. Concurrent use of molecular targeted therapy.
  23. Tested HIV sero-positivity or tested active hepatitis B or C infection.
  24. Participation in another clinical study with other investigational drugs within 14 days prior to randomization.
  25. Vaccination within 1 month prior to randomization.
  26. Any medical, mental, psychological or psychiatric condition (particularly severe depression, suicidal ideation or suicide attempt) that in the opinion of the investigator would not permit the patient to complete the study or comply to study procedures.
  27. Drug and/or alcohol abuse.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03117816


Contacts
Layout table for location contacts
Contact: Andreas Burchert, Prof. Dr. 0049 6421 586 ext 5611 burchert@staff.uni-marburg.de
Contact: Kerstin Balthasar 0049 6421 286 ext 6558 kerstin.balthasar@kks.uni-marburg.de

Locations
Layout table for location information
France
Institut Bergonié Not yet recruiting
Bordeaux, France, 33076
Contact: Gabriel Etienne, MD    +33 (0)5 5633 ext 0448    g.etienne@bordeaux.unicancer.fr   
Centre Léon Bérard Not yet recruiting
Lyon, France, 69373
Contact: Franck E. Nicolini, MD, PhD, HDR    ++33 (0)4 7878 ext 2737    Franck-Emmanuel.NICOLINI@lyon.unicancer.fr   
CHRU de Nancy - Hôpitaux de Brabois Not yet recruiting
Vandœuvre-lès-Nancy, France, 54500
Contact: Agnès Guerci-Bresler, MD    +33 (0)3 8315 ext 3282    a.guerci@chu-nancy.fr   
Germany
Universitätsklinikum Aachen Recruiting
Aachen, Germany, 52074
Contact: Martina Crysant, MD    ++49 241 80 ext 80591    mcrysandt@ukaachen.de   
Contact: Tim H. Brümmendorf, Prof    ++49 241 80 ext 89805    tbruemmendorf@ukaachen.de   
Principal Investigator: Martina Crysant, MD         
Studienzentrum Aschaffenburg Recruiting
Aschaffenburg, Germany, 63739
Contact: Martine Klausmann, MD    ++49 6021-342 ext 780    mk@klausmann.de   
Contact: Silke Schirrmacher-Memmel, MD    ++49 6021-342 ext 780    sm@klausmann.de   
Universitätsmedizin Berlin Charite- Campus Virchow Klinikum Recruiting
Berlin, Germany, 13353
Contact: Philipp Le Courte, MD    ++49 30 450 665 ext 307    philipp.lecoutre@charite.de   
Contact: Theo Kim, MD    ++49 30 450 ext 513077    theo.kim@charite.de   
Principal Investigator: Philipp Le Courte, MD         
Universitätsklinikum Bonn, Medizinische Klinik und Poliklinik III Recruiting
Bonn, Germany, 53105
Contact: Jai-Jün Shiue, MD    ++49 228 287 17 ext 233    jai-juen.shiue@ukb.uni-bonn.de   
Contact: Lino Teichmann, MD    0228-287 51 ext 630    lino.teichmann@ukb.uni-bonn.de   
Klinikum Bremen Mitte, Medizinische Klinik I Recruiting
Bremen, Germany, 28177
Contact: Matthias Bormann, Dr.med.    ++49 421 497 ext 5132    matthias.bormann@klinikum-bremen-mitte.de   
Contact: Bernd Hertenstein, Prof    ++49 421 497 ext 5240    bernd.hertenstein@klinikum-bremen-mitte.de   
BAG / Onkologische Gemeinschaftspraxis Recruiting
Dresden, Germany, 01307
Contact: Thomas Illmer, PD Dr.    ++49 351 44000 ext 22    illmer@onkologie-dresden.net   
Contact: Jens Freiberg-Richter, Dr. med.    ++49 351 44000 ext 22    freiberg-richter@onkologie-dresden.net   
Universitätsklinikum Düsseldorf Recruiting
Dusseldorf, Germany, 40225
Contact: Norbert Gattermann, Prof    +49 211- 81 ext 16500    gattermann@med.uni-duesseldorf.de   
Contact: Judith Strapatsas (née Neukirchen), MD    +49 211- 81 ext 17720    judith.strapatsas@med.uni-duesseldorf.de   
Principal Investigator: Norbert Gattermann, Prof         
Universitätsklinikum Erlangen Recruiting
Erlangen, Germany, 91054
Contact: Stefan Krause, Prof    ++49 9131 85 ext 35957    stefan.krause@uk-erlangen.de   
Contact: Norbert Meidenbauer, PD, MD    ++49 9131 85 ext 36766    norbert.meidenbauer@uk-erlangen.de   
Principal Investigator: Stefan Krause, Prof         
Universitätsklinikum Essen, Klinik für Hämatologie Recruiting
Essen, Germany, 45147
Contact: Joachim Goethert, MD    ++49 201 723 84 ext 729    joachim.goethert@uk-essen.de   
Contact: Maher Hanoun, MD    0201 723 83 ext 847    maher.hanoun@uk-essen.de   
Klinikum der Goethe Universität, Medizinische Klinik II Recruiting
Frankfurt a. Main, Germany, 60590
Contact: Fabian Lang, Dr.med.    ++49 69 6301 ext 4013    fabian.lang@kgu.de   
Contact: Jörg Chromik, Dr.med.    ++49 69 6301 ext 6103    joerg.chromik@kgu.de   
Universitätsklinikum Hamburg Eppendorf Recruiting
Hamburg, Germany, 20246
Contact: Philippe Schafhausen, Dr. med.    +49 40 7410 ext 57122    schafhausen@uke.de   
Contact: Snjezana Janjetovic, Dr. med.    +49 40 7410 ext 50661    s.janjetovic@uke.de   
Evangelische Krankenhaus Hamm gGmbH Recruiting
Hamm, Germany, 59063
Contact: Elisabeth Lange, MD    0049 2381 90583 ext 25    marianne.david@valeo-kliniken.de   
Contact: Thomas Wehler, Prof. Dr.    0049 2381 589 ext 1863    onkologie.hamm@valeo-kliniken.de   
Onkologische Praxis Heilbronn Withdrawn
Heilbronn, Germany, 74072
Universitätsklinikum Jena Recruiting
Jena, Germany, 07740
Contact: Andreas Hochhaus, Prof    +49 3641 932 ext 4200    Andreas.Hochhaus@med.uni-jena.de   
Contact: Thomas Schenk, MD    +49 3641 939 ext 6661    thomas.schenk@med.uni-jena.de   
Principal Investigator: Andreas Hochhaus, Prof         
Institut für Versorgungsforschung in der Onkologie GbR Recruiting
Koblenz, Germany, 56068
Contact: Christoph Lutz, MD    0261-9215 ext 6930    lutz@invo-koblenz.de   
Contact: Rudolf Weide, Prof. Dr. med.    0261-9215 ext 6930    weide@invo-koblenz.de   
Universitätsklinikum Leipzig Recruiting
Leipzig, Germany, 04103
Contact: Georg-Nikolaus Franke, MD    ++49 341 97 ext 13020    Georg-Nikolaus.Franke@medizin.uni-leipzig.de   
Contact: Song-Yau Wang, MD    ++49 341 97 ext 13030    song-yau.wang@medizin.uni-leipzig.de   
Principal Investigator: Georg-Nikolaus Franke, MD         
Johannes-Gutenberg-Universität III. Medizinische Klinik Recruiting
Mainz, Germany, 55131
Contact: Thomas Kindler, PD, MD    ++49 6131 17 ext 5046    thomas.kindler@unimedizin-mainz.de   
Contact: Markus Radsak, Prof    ++49 6131 17 ext 5947    radsak@uni-mainz.de   
Principal Investigator: Thomas Kindler, PD, MD         
Universitätsmedizin Mannheim Recruiting
Mannheim, Germany, 68169
Contact: Susanne Saussele, PD, MD    ++49 621-383 ext 6966    Susanne.Saussele@medma.uni-heidelberg.de   
Contact: Henning Popp, MD    ++49 621-383 ext 4115    henning.popp@medma.uni-heidelberg.de   
Principal Investigator: Susanne Saussele, PD, MD         
Universitätsklinikum Gießen und Marburg GmbH Recruiting
Marburg, Germany, 35043
Contact: Andreas Burchert, Prof.    +49 6421 586 ext 6511    burchert@staff.uni-marburg.de   
Contact: Stephan K. Metzelder, MD    +49 6421 586 ext 2724    metzelde@med.uni-marburg.de   
Principal Investigator: Andreas Burchert, Prof.         
Universitätsklinikum Münster Recruiting
Muenster, Germany, 48149
Contact: Eva Esseling, MD    ++49 251 83 ext 52807    eva.esseling@ukmuenster.de   
Contact: Jan-Henrik Mikesch, MD    ++49 251 83 ext 52818    Jan-Henrik.Mikesch@ukmuenster.de   
Principal Investigator: Eva Schmidt, MD         
III. Medizinischen Klinik TUM Klinikum rechts der Isar Recruiting
Munich, Germany, 81675
Contact: Philipp Jost, PD, MD    ++49 89 4140 ext 5941    philipp.jost@tum.de   
Contact: Stefanie Jilg, MD    ++49 89 4140 ext 4111    stefanie.jilg@tum.de   
Principal Investigator: Philipp Jost, PD, MD         
Universitätsklinikum Tübingen Recruiting
Tubingen, Germany, 72076
Contact: Robert Möhle, Prof    ++40 7071-29 ext 83179    robert.moehle@med.uni-tuebingen.de   
Contact: Martin Sökler, MD    ++40 7071-29 ext 80686    martin.soekler@med.uni-tuebingen.de   
Principal Investigator: Robert Möhle, Prof         
Universitätsklinikum Ulm Recruiting
Ulm, Germany, 89081
Contact: Frank Stegelmann, MD    ++49 731-500 ext 45521    frank.stegelmann@uniklinik-ulm.de   
Contact: Konstanze Döhner, Prof    ++49 731-500 ext 45505    konstanze.doehner@uniklinik-ulm.de   
Principal Investigator: Frank Stegelmann, MD         
Universitätsklinikum Würzburg, Zentrum für Innere Medizin Recruiting
Würzburg, Germany, 97080
Contact: Maria-Elisabeth Goebeler, Dr.med.    ++49 931 201 ext 40966    goebeler_m@ukw.de   
Contact: Volker Kunzmann, Prof. Dr. med.    ++49 931 201 ext 40004    kunzmann_v@ukw.de   
Sponsors and Collaborators
Philipps University Marburg Medical Center
Deutsche Krebshilfe e.V., Bonn (Germany)
AOP Orphan Pharmaceuticals AG
Investigators
Layout table for investigator information
Study Director: Andreas Burchert, Prof. Dr. Philipps University Marburg Medical Center
Principal Investigator: Franck E Nicoloni, MD, PhD Centre Léon Bérard Lyon

Publications:
Mahon, F., Richter, J., Guilhot, J., Muller, M. C., Dietz, C., Porkka, K., Hjorth-Hansen, H., Gruber, F., Panagoitidis, P., Ossenkoppele, G. J., Mayer, J., Almeida, A., Machova Polakova, K., Ehrencrona, H., Kairisto, V., Berger, M. G., Olsson stromberg, U., Mustjoki, S., Hochhaus, A., Pfirrmann, M., & Saussele, S. (2014). Interim Analysis of a Pan European Stop Tyrosine Kinase Inhibitor Trial in Chronic Myeloid Leukemia : The EURO-SKI study. Blood, 124(21), 151. Accessed March 07, 2017. Retrieved from http://www.bloodjournal.org/content/124/21/151.

Layout table for additonal information
Responsible Party: Kerstin Balthasar, KKS Marburg Sponsor representative, Philipps University Marburg Medical Center
ClinicalTrials.gov Identifier: NCT03117816     History of Changes
Other Study ID Numbers: KKS-227
2016-001030-94 ( EudraCT Number )
First Posted: April 18, 2017    Key Record Dates
Last Update Posted: May 21, 2019
Last Verified: May 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Kerstin Balthasar, Philipps University Marburg Medical Center:
deep molecular remission of MR4 or better

Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia
Leukemia, Myeloid
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Neoplasms by Histologic Type
Neoplasms
Myeloproliferative Disorders
Bone Marrow Diseases
Hematologic Diseases
Interferons
Interferon alpha-2
Interferon-alpha
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Immunologic Factors
Physiological Effects of Drugs